BMEA — Q2 2026 Financial Report Analysis

Overview

Biomea Fusion is a clinical-stage drug developer. It has no approved products and no revenue at all, so there's no sales growth to measure. What matters for a company like this is how fast it spends cash, how long that cash lasts, and whether its trials produce results before the money runs out. In the second quarter of 2026 (April–June) it cut spending sharply. The net loss fell to $8.3 million from $20.7 million a year earlier. Cash fell to $35.2 million, and the company still warns of "substantial doubt" about its ability to keep operating without raising more money.

Its two drug candidates, in plain terms:

• Icovamenib (formerly BMF-219) is a once-a-day pill that blocks a protein called menin. In the company's words, menin "serves as a checkpoint to prevent beta cell proliferation". Beta cells are the pancreas cells that make insulin. The bet is that releasing this brake lets the body grow or keep more working insulin-producing cells, so diabetes is treated at its cause rather than only by lowering blood sugar.
• BMF-650 is an experimental oral GLP-1 drug for obesity. It works the same way as the injectable weight-loss drugs in the Ozempic/Wegovy class, but it is taken as a pill.

At a glance

• Net loss $8.3M, down 60% from $20.7M. About two-thirds of the $12.4M improvement is real cost cutting (the operating loss shrank $8.5M). Most of the rest is a non-cash accounting gain of $4.1M, explained below.
• Cash of $35.2M, down $9.9M in the quarter. Management says this lasts "into the second quarter of 2027". That's roughly the moment its two main diabetes trials are due to report.
• 72.4M weighted-average shares, up 78% from 40.6M. Raising cash in 2025 nearly doubled the share count, which is why loss per share fell faster than the loss itself.

Key figures

All figures in US$ millions except per-share amounts. Biomea has no revenue, so revenue and operating margin (the share of revenue left after running the business) don't apply here.

Source: Form 10-Q for the quarter ended June 30, 2026, and the Q2 earnings release (Exhibit 99.1, filed August 5, 2026). Q1 2026 cash is from the Q1 earnings release.

Takeaway: Biomea has cut its spending roughly in half, but cash on hand only reaches about the point where its two key diabetes trials report (Q1 and Q2 2027). It will almost certainly have to sell more stock before shareholders find out whether icovamenib works. A share offering launched on September 22, 2026 shows that is already happening.

Where the spending cuts came from

Most of the lower loss comes from a smaller operation, not from one cheaper item:

• R&D fell $7.4M (to $9.1M). The 10-Q breaks this down as follows: $1.5M less on preclinical and exploratory programs, $1.3M less on outside consultants and advisors, $1.0M less on manufacturing, $2.5M less on personnel "due to a decrease in headcount", and $1.7M less on rent and facilities. Clinical-trial spending actually rose $0.6M. In other words, the cuts hit everything except the trials themselves, which is what you'd want to see.
• G&A fell $1.1M (to $3.6M), mainly $0.9M of lower personnel costs, also from headcount reductions.
• The company has narrowed its focus. It stopped studying icovamenib in cancer and plans to look for a partner for its cancer asset BMF-500, so it can spend only on diabetes and obesity.

What the headline numbers hide

• About $4.1M of the improvement isn't operating at all. The warrants issued in Biomea's June and October 2025 stock sales are rights to buy about 35.2 million shares at $2.50. Accounting rules record them as a liability and revalue them every quarter. When Biomea's share price falls, the warrants are worth less and the company books a gain. In Q2 that gain was $4.1M. So the net loss looks better partly because the stock fell. The operating loss of $12.8M is the cleaner measure of the business. It is still 40% smaller than a year ago.
• Cash burn sits between the two loss figures. Cash fell $9.9M in Q2 ($45.1M to $35.2M), less than the $12.8M operating loss. Part of the gap is $1.6M of stock-based pay, which costs no cash. First-half operating cash outflow was $21.7M, against $44.9M a year earlier. The first half also included a one-off $0.5M gain from selling equipment.
• Runway math. $35.2M divided by about $10M a quarter is about 3.5 quarters, which lines up with management's "into the second quarter of 2027". The runway guidance moved out by one quarter, from "into the first quarter of 2027" in the Q1 release. That came from spending less, not from new money. No shares were sold through the at-the-market program (selling shares gradually on the open market) in the first half of 2026, and financing brought in only $0.2M.
• Going-concern warning. The 10-Q states plainly: "there is substantial doubt about our ability to continue as a going concern". Management says that without new capital it cannot continue as a going concern "over the next twelve months". The accumulated deficit (total losses since the company was founded) is $469.8M. Shareholders' equity is only $12.1M, and $14.3M of liabilities are the non-cash warrant liability.
• Dilution is the cost of staying alive. The June 2025 stock sale was at $2.00 a share and the October 2025 one at $2.05. Earlier sales were far higher, for example $30.00 in April 2023. On September 21, 2026 the stock closed at $1.71 (per the new prospectus), below the $2.50 exercise price of the outstanding warrants. That makes it unlikely those warrants bring in cash any time soon.

What happened after the quarter

• A new stock offering. On September 22, 2026, Biomea filed a preliminary prospectus for an underwritten sale of common stock and pre-funded warrants (rights that work almost like shares, sold to some investors instead of shares), led by Konik Capital Partners. The underwriter also gets warrants for 7% of the shares sold, plus an option to buy 15% more. The preliminary filing leaves the price and size blank. As of this writing, no final pricing filing appears on EDGAR, so we can't yet say how much it raised or how much it dilutes existing holders.
• BMF-650 obesity data slipped by a few weeks. In August, initial 28-day weight-loss data from the Phase I GLP-131 trial was guided for Q3 2026. An 8-K on September 22 moved topline results to October 2026. Note the timing: the company is selling stock just ahead of that readout, not after it.

Pipeline and what to watch

The type 1 diabetes data shown at the American Diabetes Association meeting was encouraging but very small. Three recently diagnosed patients on 200 mg had a 52% rise from baseline in C-peptide at week 12. C-peptide is a marker of how much insulin the body makes by itself. Most of that rise held through week 52. With three patients, this is a reason to run a bigger trial, not evidence that the drug works.

Outlook

Management's own guidance is cash "into the second quarter of 2027" and Phase II type 2 diabetes data in Q1 and Q2 2027. Our read: the cost cutting is real and well targeted, because trial spending went up while everything else came down. But the company runs out of cash at about the same time its most important data arrives. That's why it is raising money now, at under $2 a share, before either readout. Three things will decide the next six months:

1. The BMF-650 data in October. Oral GLP-1 obesity drugs face crowded competition, and the 10-Q itself notes the Wegovy pill was approved in December 2025.
2. The final size and price of the September offering, which sets how much the share count grows and how far the runway extends.
3. Whether COVALENT-211 stays on track for Q1 2027. A delay would push the key result past the point where the current cash runs out.

Until a trial produces a clear result, investors should expect losses of roughly $8–13 million a quarter and more share sales to pay for them.